



UNIVERSITY OF LEEDS

This is a repository copy of *First pilot study of extracellular volume MRI measurement in peripheral muscle of systemic sclerosis patients suggests diffuse fibrosis.*

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/176366/>

Version: Accepted Version

Article:

Dumitru, R, Goodall, A, Broadbent, D et al. (4 more authors) (2021) First pilot study of extracellular volume MRI measurement in peripheral muscle of systemic sclerosis patients suggests diffuse fibrosis. *Rheumatology*. ISSN 1462-0324

<https://doi.org/10.1093/rheumatology/keab567>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

**First pilot study of extracellular volume MRI measurement
in peripheral muscle of systemic sclerosis patients suggests
diffuse fibrosis**

Journal:	<i>Rheumatology</i>
Manuscript ID	RHE-21-0909.R1
Manuscript Type:	Concise Report
Date Submitted by the Author:	03-Jun-2021
Complete List of Authors:	<p>Dumitru, Raluca; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine; Leeds Biomedical Research Centre, NIHR Leeds Biomedical Research Centre</p> <p>Goodall, Alex ; Leeds Teaching Hospitals NHS Trust, Department Of Medical Physics and Engineering; Sheffield Teaching Hospitals NHS Foundation Trust, Department of Medical Imaging and Medical Physics</p> <p>Broadbent, David ; Leeds Teaching Hospitals NHS Trust, Department Of Medical Physics and Engineering</p> <p>Del Galdo, Francesco; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine; Leeds Biomedical Research Centre, NIHR Leeds Biomedical Research Centre</p> <p>Tan, Ai Lyn; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine; Leeds Biomedical Research Centre, NIHR Leeds Biomedical Research Centre</p> <p>Biglands, John; Leeds Teaching Hospitals NHS Trust, Department Of Medical Physics and Engineering; Leeds Biomedical Research Centre, NIHR Leeds Biomedical Research Centre</p> <p>Buch, Maya; The University of Manchester, Centre for Musculoskeletal Research; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine</p>
Keywords Please select a minimum FIVE keywords from the list provided. These keywords will be used to select reviewers for this manuscript. The keywords in the main text of your paper do not need to match these words.:	Scleroderma and related disorders < RHEUMATIC DISEASES, Muscle < TISSUES, MRI < DIAGNOSTIC METHODS, Laboratory diagnosis < DIAGNOSTIC METHODS, Diagnostic imaging < DIAGNOSTIC METHODS

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 **First pilot study of extracellular volume MRI measurement in peripheral muscle of systemic**
4
5 **sclerosis patients suggests diffuse fibrosis**
6
7

8 Authors: *Raluca Dumitru^{1,2}, * Alex Goodall^{3,4}, David Broadbent³, Francesco Del Galdo^{1,2}, Ai Lyn Tan¹
9
10 ², *John Biglands^{2,3}, *Maya Buch^{1,5,6}
11
12

13 * Equal contribution
14
15

16 **Affiliations:**
17
18

19 ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United
20
21 Kingdom
22

23
24 ²Leeds Biomedical Research Centre, National Institute for Health Research, Leeds, United Kingdom
25
26

27 ³Department Of Medical Physics and Engineering, Leeds Teaching Hospitals NHS Trust, Leeds, United
28
29 Kingdom
30
31

32 ⁴Department of Medical Imaging and Medical Physics, Sheffield Teaching Hospitals Foundation Trust,
33
34 Sheffield, United Kingdom
35
36

37 ⁵Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine &
38
39 Health, University of Manchester, Manchester, United Kingdom
40
41

42 ⁶NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust,
43
44 Manchester Academic Health Science Centre, University of Manchester, Manchester, United
45
46 Kingdom
47
48

49 **Corresponding author**
50
51

52 Professor Maya H Buch
53
54

55
56 AV Hill Building, Acker Street, Centre for Musculoskeletal Research, School of Biological Sciences,
57
58 Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK, M13 9PL
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Email: maya.buch@manchester.ac.uk

ORCID ID: <https://orcid.org/0000-0002-8962-5642>

Telephone: +44 (0)161 306 0696

For Peer Review

Abstract

Objectives

Peripheral muscle involvement in systemic sclerosis (SSc) may comprise myositis or a non-inflammatory myopathy. There is little understanding on the nature of SSc myopathy. This pilot study aimed to evaluate for the presence of diffuse fibrosis in the peripheral muscle of patients with SSc by determining extracellular volume (ECV) MRI measurement.

Methods

SSc patients, with suspected myopathy or no muscle involvement, and healthy volunteers (HV) had native T1 and ECV MRI quantification of the thigh and creatine-kinase (CK) measured. Suspected myopathy was defined as current/history of minimally raised CK (<600 IU/l) +/- presence of clinical signs-symptoms (proximal muscle weakness and/or myalgia) +/- a Manual Muscle Testing score <5 in the thighs.

Results

12 SSc patients and 10 HV were recruited. 9/12 patients had limited cutaneous SSc, 4/12 interstitial lung disease, 7/12 suspected myopathy. Higher skeletal muscle ECV was recorded in SSc patients compared to HV [mean (SD) 23(11)%, vs 11(4)% p=0.04].

Peripheral muscle ECV associated with CK ($\rho=0.554$, $p=0.061$) and was higher in SSc patients with myopathy compared to those with no myopathy [mean (SD) 28 (10) vs 15 (5), $p=0.023$]. An ECV of 22% was determined to best identify myopathy with a sensitivity of 71% and a specificity of 80%.

Conclusion

This hypothesis-generating study showed higher ECV in SSc patients compared to HV as well as association of ECV with suspected myopathy, suggesting the presence of diffuse fibrosis in the peripheral muscle of SSc patients. Further studies are needed to understand the nature of SSc myopathy.

1
2
3 **Keywords:** systemic sclerosis myopathy, extracellular volume magnetic resonance, diffuse fibrosis
4
5

6 **Key messages:**
7

- 8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- A first study to implement extracellular volume (ECV) MRI measurement in the peripheral muscle of SSc patients
 - Higher ECV, suggesting diffuse fibrosis in SSc patients compared to controls, and in SSc patients with suspected myopathy was observed
 - ECV MRI may be useful in identifying and understanding the nature of SSc peripheral muscle involvement

For Peer Review

Introduction

Peripheral muscle involvement in systemic sclerosis (SSc; SSc myopathy) represents a significant cause of disability and is associated with increased mortality (1, 2). The prevalence of SSc myopathy ranges widely, depending on the definition and diagnostic modalities used, with estimates of between 10% to 90% (3-5). Its pathogenesis is complex and in line with SSc pathology, stigmata of microangiopathy, fibrosis and inflammation have been described at the histopathological level (3, 6).

There is no formal definition or classification criteria for SSc peripheral muscle involvement, which is partly attributable to the heterogenous nature of muscle involvement as well as the lack of new evidence investigating SSc myopathy. The majority of studies focus on the inflammatory pattern, which resembles that of dermatomyositis/polymyositis and typically subsides with immunosuppressive treatment (4, 7, 8). A non-inflammatory pattern is also recognised, being characterised by modest proximal weakness, poor endurance and mildly elevated creatine kinase (CK) levels (4, 8).

T1 mapping with extracellular volume (ECV) quantification is now widely used in cardiovascular magnetic resonance (CMR) to assess interstitial and diffuse processes, particularly diffuse fibrosis, in various cardiac pathologies. Multiple studies show good association of CMR mapping measurements with histological findings of myocardial interstitial fibrosis and increasing data demonstrate elevated CMR ECV, including in SSc (9-11) . More recently, T1 mapping and ECV measurement has been successfully applied in other pathologies and organs including the liver, spleen, kidney and brain (12-14). Higher ECV has also been demonstrated in the thoracic muscle visible at the edge of the CMR field in amyloidosis, idiopathic inflammatory myopathy as well as SSc (11, 12, 15). No studies to date have *a priori* measured ECV in the peripheral muscle of SSc patients using a dedicated protocol.

The current study aimed to assess the feasibility of ECV measurement for evaluating the presence of diffuse fibrosis in the peripheral muscle of SSc patients. The feasibility of measuring ECV in the peripheral muscle of healthy volunteers was previously undertaken and has been reported (16).

Methods

Participants

Participants were recruited from The Leeds Teaching Hospital and consented to the 'MUSCLE II study: Contrast-Enhanced MRI scan', that allowed contrast administration. The study was conducted according to the Declaration of Helsinki with approval from the Yorkshire & The Humber - Leeds East Research Ethics Committee (RR17/92933, REC ref:17/EM/0079). All participants provided written informed consent.

All patients fulfilled the 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for SSc (17). Two SSc groups were included in the study: participants with no muscle involvement and participants with suspected myopathy. Suspected myopathy was defined as current/history of minimally raised CK (>320; <600 IU/l) +/- presence of clinical signs-symptoms (including proximal lower limb muscle weakness and/or myalgia) +/- a Manual Muscle Testing (MMT) 8 score <5 in the thighs. Participants with no muscle involvement were defined as SSc patients with a MMT score >5 in the thighs, with no history of raised CK or clinical features including muscle weakness or myalgia. Patients were excluded if they had a confirmed diagnosis of myositis or any known degenerative muscle disease, an immune mediated inflammatory disease (IMID) other than SSc, if they were receiving treatment with and/or equivalent of more than 5 mg of prednisolone and/or lipid lowering treatment with statins.

Ten healthy volunteers (HV) with no muscle pathology and no statin or steroid use were also recruited and had a peripheral muscle MRI with T1 measurements and ECV quantification.

Data collection

All patients had demographic and clinical data collected, including SSc subtype, disease duration, treatment, organ involvement. Patients were questioned for proximal lower limb muscle weakness and/or myalgia and muscle strength was tested by the same assessor (RBD), using the standardised

1
2
3 MMT 8 score (18). Routine blood tests including full blood count C-reactive protein (CRP) and
4
5 creatine kinase (CK) were measured at the visit/within 4 weeks from the study visit. Any history of
6
7 repeatedly minimal CK elevation (<600 IU/l) was also recorded. As part of standard care, all patients
8
9 had ANA screen (multiplex flow immunoassay, Bioplex 2200) and myositis-associated antibody panel
10
11 was performed upon specific clinical request. These were tested at the Leeds Teaching Hospital NHS
12
13 Trust and the results retrospectively collected.
14
15

16 17 MRI protocol

18
19
20 Both SSc patients and HV underwent MRI imaging of the dominant thigh on a Siemens Verio 3 T
21
22 scanner (Siemens Healthineers, Erlangen, Germany). The MRI protocol and image analysis has been
23
24 fully described (16). T1 measurements were performed using an inversion recovery steady-state free
25
26 precession sequence. Pre and 20 minutes post contrast acquisitions were acquired for the thigh and
27
28 the abdominal aorta. Regions of Interest (ROI)s within the vastus intermedius and the abdominal
29
30 aorta were drawn for each participant. ECV was calculated as previously reported (16).
31
32

33
34 MATLAB (MATLAB R2015a, The MathWorks Inc., Natick, MA, 2015) and ImageJ (ImageJ 1.51k,
35
36 National Institute of Health, Maryland, USA) were used for image analysis.
37
38

39 Statistical analysis

40
41
42 The statistical analysis was performed using SPSS (IBM SPSS Statistics 22) and GraphPad Prism V8.
43
44 Descriptive summary statistics are provided for all variables. Continuous variables are reported as
45
46 mean (SD) or median (IQR) and categorical data reported as percentage. Student's t-test, chi square
47
48 test, Fischer exact test or Mann-Whitney U test when appropriate were used to assess for
49
50 differences between groups. Correlation of clinical and serum biomarkers and MRI measures were
51
52 assessed by Spearman's or Pearson rho test. For exploratory purposes, Receiver-operating
53
54 characteristic (ROC) curves and Youden test were used to assess the ability of muscle ECV for
55
56 identifying myopathy.
57
58
59
60

1
2
3 As this was a small pilot study, p-values are reported to only ascribe strength of descriptive
4 differences rather than assign definitive significance, in line with good practice (19).
5
6
7

8 **Results**

9

10
11 Twelve SSc patients participated in the study with a median (IQR) age and disease duration of 52 (41,
12 65) and 7 (2, 17) years respectively. The cohort included ten (83%) females, and nine limited
13 cutaneous SSc (lcSSc) (Table 1). The median (IQR) modified Rodnan skin score (mRSS) was 3 (1,4),
14 one patient had arthritis and four had a history of digital ulcers (DU) and interstitial lung disease
15 (ILD). None of the patients had a confirmed diagnosis of pulmonary hypertension or cardiac
16 involvement. All patients had positive antinuclear antibodies (ANA): five anti-topoisomerase
17 antibody (Scl70), four anticentromere antibody (ACA) and three had myositis associated antibodies
18 (MSA): two Pm/Scl70 positive and one Anti Ro antibody. Seven SSc patients were receiving
19 treatment with disease modifying anti-rheumatic drugs (DMARD), five on mycophenolate mofetil
20 and two on methotrexate. Two patients were on minimal corticosteroid treatment, one patient
21 receiving 5 mg daily and the other patient receiving 2.5 mg of prednisolone.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Ten HV (six females) were included in the study, with a median (IQR) age of 36 (33-40). None had
38 muscle pathology, and none were receiving any medication.
39
40
41

42 **Muscle MRI finding in HV compared to SSc patients**

43

44
45 Higher skeletal muscle ECV was noted in SSc patients compared to HV [mean (SD) 23 (11)% vs
46 11(4)%, mean diff (95%CI) -12 (-19, -40)%, p=0.04]. Skeletal muscle native T1 values were
47 comparable between the 2 groups although modestly higher in SSc patients compared to HV [mean
48 (SD) 1396 (56) ms vs 1387 (42) ms, mean diff (95%CI) -8 (-53, 37) ms] (Figure 1).
49
50
51
52
53
54
55
56
57
58
59
60

Peripheral muscle MRI and association with disease phenotype

Except for a positive association between peripheral muscle T1 native and a lcSSc subset ($\rho=0.641$, $p=0.025$), no other association with disease characteristic, including a diagnosis of ILD, history of DU, disease duration, arthritis, mRSS, or antibodies was found. All 3 patients with MSA had a suspected myopathy: 1 patient (Anti Ro) had muscle weakness and a MMT score of 4/5 involving the hip adductors, one patient had increased CK levels at the time of the visit, and one had a history of repeatedly raised CK levels.

Muscle MRI findings in SSc patients with myopathy

Seven of the twelve SSc patients had a diagnosis of suspected myopathy. Four patients reported proximal muscle weakness and had a MMT score of 4/5 involving the hip adductors, of whom three also had a history of CK elevation, one patient had a history of proximal lower limb muscle weakness, and another two patients had a history of CK elevation of whom one had increased CK levels at the time of the visit (400 IU/l).

Peripheral muscle ECV associated with CK ($R^2=0.307$, $\rho=0.554$, $p=0.062$) and higher ECV values were found in those with myopathy compared to those with no muscle involvement [mean (SD) 28 (10)% vs 15 (5)%, mean diff (95%CI)-13 (-24, -3)%, $p=0.023$]. There was no difference in T1 native between those with and without myopathy [mean (SD) of 1395 (73) ms vs 1395 (26) ms, mean diff (95%CI) 0.08 (-77, 77) ms, $p=0.998$] (Figure 2).

For exploratory purposes, a ROC curve was performed to find potential cut-off values of muscle ECV for identifying myopathy. AUC (95%CI) was strongest at 0.886 (-0.690, 1)%, $p=0.028$. Using Youden test, an ECV value of 22% was found to best identify myopathy with a sensitivity of 71% and a specificity of 80%.

Discussion

This hypothesis testing pilot study demonstrated the feasibility of using ECV to evaluate the presence of diffuse fibrosis in the peripheral muscle of SSc patients. Higher ECV was noted in SSc patients compared to HV and in SSc patients with a myopathy compared to those without, suggesting the presence of diffuse fibrosis in the peripheral muscle of SSc patients, which may represent the substrate for the non-inflammatory myopathy. These data can inform larger studies to explore the significance of interstitial fibrosis in the peripheral muscle.

The study was a first to use ECV as a marker of diffuse fibrosis in the peripheral muscle, employing a dedicated skeletal muscle protocol. Higher ECV was observed in the peripheral muscle of SSc patients compared to HV. Previous studies have measured skeletal muscle ECV in patients with amyloidosis, idiopathic inflammatory myopathy as well as SSc, although using the thoracic muscle visible at the edge of the CMR field (11, 12, 15), which may be more susceptible to errors than a dedicated skeletal muscle protocol. Our study measured ECV in the peripheral muscle (vastus intermedius) the main muscle group affected in SSc and other IMID, as opposed to axial muscle, minimising cardiac and breathing artefacts and providing larger muscle volume for T1 measurement.

Muscle ECV values of HV were comparable to those reported in the literature, however, there were significant discrepancies between the muscle T1 native values of HV and ECV values of SSc patients compared to other studies (11, 20). These discrepancies are likely due to the limitations of the cardiac T1 measurement sequences, which have to contend with cardiac gating, rather than errors in our skeletal muscle sequences, which used a pure, single readout per inversion method.

Patients presenting with suspected myopathy had greater ECV compared to the non-myopathy group, demonstrating the potential value of ECV in detecting low-grade muscle pathology. A muscle ECV of 22% was found to best identify myopathy in this cohort. CK was also associated with ECV, albeit only one patient had a CK above the normal value and three more had intermittently

1
2
3 minimally raised CK, suggesting the potential clinical importance of low level CK in detecting muscle
4
5 abnormalities. Other studies have documented the association of low level CK with impaired muscle
6
7 strength, abnormalities on EMG as well as biopsy findings of fibrosis (1, 4).
8
9

10
11 Except for a positive association of lcSSc and ECV, likely reflecting the small sample size, with the
12
13 majority of patients (9/12) having lcSSc, no other association with clinical characteristics was found.
14

15 This is in accordance with other studies that reported no association between disease
16
17 characteristics, in particular poor prognostic factors of SSc and myopathy (4).
18
19

20
21 The main limitation of the study is the sample size. However, this is a novel, pilot, hypothesis-
22
23 generating study, which sought to assess the feasibility of ECV measurement in the peripheral
24
25 muscle of SSc patients. To avoid confounding, an age and gender matched HV cohort would have
26
27 been desirable. ECV can increase in the setting of both fibrosis and oedema. Muscle biopsy
28
29 evaluation would have been ideal to explore the MRI findings of increased ECV although not feasible
30
31 in healthy and asymptomatic patient populations. The same contrast equilibrium that was
32
33 determined in HV was applied in SSc patients. A longer time for reaching equilibrium would imply
34
35 higher ECV values in SSc patients.
36
37
38
39

40 In conclusion, this study demonstrated increased skeletal muscle ECV, suggestive of interstitial
41
42 fibrosis in the peripheral muscle of SSc patients, providing pathophysiological insights into non-
43
44 inflammatory myopathy in SSc. T1 measurement with ECV quantification may therefore be a
45
46 valuable imaging tool to characterise peripheral muscle in SSc. Further research is needed to validate
47
48 the findings of this pilot study and identifying the prognostic value of interstitial fibrosis in the
49
50 peripheral muscle of SSc patients.
51
52
53
54
55
56
57
58
59
60

1
2
3 **Funding:** The research is supported by the National Institute for Health Research (NIHR)
4
5 infrastructure at Leeds.
6
7

8
9 **Competing interests:** The authors have declared no conflicts of interest.
10

11
12 **Acknowledgments:** The authors would like to acknowledge Professor David Buckley for advice and
13
14 expertise in designing the ECV measurements. The views expressed are those of the author(s) and
15
16 not necessarily those of the NHS, the NIHR or the Department of Health. Dr Dumitru has been
17
18 funded by the Charitable Foundation Fellowship, Leeds Teaching Hospital. Dr Biglands is funded by a
19
20 National Institute of Health Research (NIHR) Clinical Lecturship (ICA-CL-2016-02-017).
21
22

23
24 **Data availability statement:** The data underlying this article are available in the article.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Jung M, Bonner A, Hudson M, Baron M, Pope JE. Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort. *Scandinavian journal of rheumatology*. 2014;43(3):217-20.
2. Pettersson H, Bostrom C, Bringby F, Walle-Hansen R, Jacobsson L, Svenungsson E, et al. Muscle endurance, strength, and active range of motion in patients with different subphenotypes in systemic sclerosis: a cross-sectional cohort study. *Scandinavian journal of rheumatology*. 2019;48(2):141-8.
3. Medsger TA, Jr., Rodnan GP, Moosy J, Vester JW. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). *Arthritis and rheumatism*. 1968;11(4):554-68.
4. Clements PJ, Furst DE, Campion DS, Bohan A, Harris R, Levy J, et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. *Arthritis and rheumatism*. 1978;21(1):62-71.
5. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Clinical and laboratory features of scleroderma patients developing skeletal myopathy. *Clin Rheumatol*. 2005;24(2):99-102.
6. Ranque B, Authier FJ, Le-Guern V, Pagnoux C, Berezne A, Allanore Y, et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies. *Ann Rheum Dis*. 2009;68(9):1474-7.
7. Carette S, Turcotte J, Mathon G. Severe myositis and myocarditis in progressive systemic sclerosis. *J Rheumatol*. 1985;12(5):997-9.
8. Paik JJ, Wigley FM, Lloyd TE, Corse AM, Casciola-Rosen L, Shah AA, et al. Spectrum of Muscle Histopathologic Findings in Forty-Two Scleroderma Patients With Weakness. *Arthritis Care Res (Hoboken)*. 2015;67(10):1416-25.
9. de Meester de Ravenstein C, Bouzin C, Lazam S, Boulif J, Amzulescu M, Melchior J, et al. Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T. *J Cardiovasc Magn Reson*. 2015;17:48.
10. Ntusi NA, Piechnik SK, Francis JM, Ferreira VM, Rai AB, Matthews PM, et al. Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis--a clinical study using myocardial T1-mapping and extracellular volume quantification. *J Cardiovasc Magn Reson*. 2014;16:21.
11. Barison A, Gargani L, De Marchi D, Aquaro GD, Guiducci S, Picano E, et al. Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance. *Eur Heart J Cardiovasc Imaging*. 2015;16(1):74-80.
12. Banypersad SM, Bandula S, Sado D, Pinney JH, Gibbs SD, Maestrini V, et al. Multiorgan ECV as measured by EQ-MRI in systemic amyloidosis. *J Cardiovasc Magn Reson*. 15: Copyright ©2013 Banypersad et al; licensee BioMed Central Ltd.; 2013. p. O34.
13. Dekkers IA, de Boer A, Sharma K, Cox EF, Lamb HJ, Buckley DL, et al. Consensus-based technical recommendations for clinical translation of renal T1 and T2 mapping MRI. *Magma (New York, NY)*. 2020;33(1):163-76.
14. Eminian S, Hajdu SD, Meuli RA, Maeder P, Hagmann P. Rapid high resolution T1 mapping as a marker of brain development: Normative ranges in key regions of interest. *PLoS One*. 2018;13(6):e0198250.
15. Huber AT, Lamy J, Bravetti M, Bouazizi K, Bacoyannis T, Roux C, et al. Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM). *Eur Radiol*. 2019;29(10):5139-47.
16. Goodall AF, Broadbent DA, Dumitru RB, Buckley DL, Tan AL, Buch MH, et al. Feasibility of MRI based extracellular volume fraction and partition coefficient measurements in thigh muscle. *Br J Radiol*. 2020;93(1111):20190931.

- 1
- 2
- 3
- 4 17. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013
- 5 classification criteria for systemic sclerosis: an American college of rheumatology/European league
- 6 against rheumatism collaborative initiative. *Ann Rheum Dis*. 2013;72(11):1747-55.
- 7 18. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary
- 8 core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory
- 9 myopathies. *Rheumatology (Oxford)*. 2001;40(11):1262-73.
- 10 19. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations
- 11 for good practice. *Journal of evaluation in clinical practice*. 2004;10(2):307-12.
- 12 20. Marty B, Coppa B, Carlier PG. Monitoring skeletal muscle chronic fatty degenerations with
- 13 fast T1-mapping. *Eur Radiol*. 2018;28(11):4662-8.
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For Peer Review

1
2
3 **Figure legends**
4

5 Figure 1. Peripheral muscle T1 mapping in healthy volunteers and SSc patients. A. ECV in HV and SSc
6 patients. B. Native T1 in HV and SSc patients
7
8

9
10 ECV, extracellular volume; HV, healthy volunteer, SSc, systemic sclerosis
11

12
13 Figure 2. Muscle extracellular volume in SSc patients with myopathy. A. Mean (SD) peripheral muscle
14 ECV in those with and without myopathy B. Mean (SD) peripheral muscle native T1 in those with and
15 without myopathy C. Correlation between peripheral muscle ECV and CK.
16
17
18

19 CK, creatine kinase; ECV, extracellular volume
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Table 1. Disease characteristics of SSc patients.

SSc phenotype	SSc patients, n=12
Demographics and disease history	
Age (years), median (IQR)	52 (41, 65)
Female, n (%)	10 (83%)
LcSSc	9 (75%)
DcSSc	3 (25%)
Disease duration (years), median (IQR)	7 (2,17)
Raynaud's duration	14 (3, 29)
History of, n (%)	
Digital ulceration	4 (33%)
Calcinosis	2 (17%)
GORD	10 (83%)
Interstitial lung disease	4 (33%)
PAH	0
Cardiac involvement	0
Clinical profile	
Total modified Rodnan skin score, median (IQR)	3 (1,4)

1
2
3
4 Presence of, n (%)
56
7 Digital ulceration 4 (33%)
8
910 Tendon friction rubs 0
11
1213 Calcinosis 3 (25%)
14
1516 Joint contractures 2 (17%)
17
1819 Any TJC 3 (25%)
20
2122 Any SJC 1 (8%)
23
2425
26
27 NFC vasculopathy pattern, n (%)
2829 Non-specific 3 (25%)
30
3132 Early 3 (25%)
33
3435 Active 4 (33%)
36
3738 Late 2 (17%)
39
4041
42
43 **Antibody profile and serology**
4445
46 Antibody positive, n (%)
4748 ANA 12 (100%)
49
5051 ACA 4 (33%)
52
5354 Scl70 5 (42%)
55
56
57
58
59
60


Pm-Scl70	2 (17%)
Ro antibodies	1 (8%)
CRP (mg/L) (normal range <5), median (IQR)	5 (5, 6)
CK (IU/l), median (IQR)	83 (53, 190)

Pulmonary function tests

FVC%, mean (SD)	107 (20)
TLC%, mean (SD)	95 (16)
DLCO%, mean (SD)	63 (19)
DLCO/VA%, mean (SD)	82 (21)


ACA, anti-centromere antibody; ANA, antinuclear antibodies; CK, creatine kinase; DcSSc, diffuse cutaneous systemic sclerosis; DLCO, diffusing capacity of the lungs for carbon monoxide; DLCO/VA, DLCO adjusted for volume; FVC, forced vital capacity; GORD, gastro-oesophageal reflux disease; IQR, interquartile range; lcSSc, limited cutaneous systemic sclerosis; NFC, nailfold capillaroscopy; NSIP, non-specific interstitial pneumonia; Scl70, anti-topoisomerase antibody; SD, standard deviation; SJC, swollen joint count; TJC, total joint count; TLC, total lung capacity.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



81x38mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



81x60mm (300 x 300 DPI)